Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks

BACKGROUND: Recycling tenofovir and lamivudine/emtricitabine with dolutegravir (TLD) after failure of non-nucleoside transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) is more tolerable and scalable than dolutegravir plus optimized nucleoside reverse transcriptase inhibitors. St...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Acquir Immune Defic Syndr
Main Authors: Keene, Claire M, Cassidy, Tali, Zhao, Ying, Griesel, Rulan, Jackson, Amanda, Sayed, Kaneez, Omar, Zaayid, Hill, Andrew, Ngwenya, Olina, van Zyl, Gert, Flowers, Tracy, Goemaere, Eric, Maartens, Gary, Meintjes, Graeme
Format: Artigo
Jezik:Inglês
Izdano: 2023
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614301/
https://ncbi.nlm.nih.gov/pubmed/36706364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000003157
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki